Last reviewed · How we verify
autologous cord blood mononuclear cells
autologous cord blood mononuclear cells is a Biologic drug developed by Guangdong Women and Children Hospital. It is currently in Phase 3 development for Treatment of cerebral palsy.
Autologous cord blood mononuclear cells are used to stimulate the body's natural repair processes.
Autologous cord blood mononuclear cells are used to stimulate the body's natural repair processes. Used for Treatment of cerebral palsy.
At a glance
| Generic name | autologous cord blood mononuclear cells |
|---|---|
| Sponsor | Guangdong Women and Children Hospital |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
This is achieved by introducing cells that have the potential to differentiate into various cell types, which can then contribute to tissue repair and regeneration. The exact mechanisms of action are not fully understood, but it is thought that these cells may help to promote healing and reduce inflammation.
Approved indications
- Treatment of cerebral palsy
Common side effects
- Graft-versus-host disease
- Infection
- Bleeding
Key clinical trials
- Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome (PHASE2)
- Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD (PHASE1)
- Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells (PHASE1, PHASE2)
- Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH) (PHASE1)
- Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children (PHASE1)
- Effect of Autologous Cord Blood-mononuclear Cells Infusion on Immune Microenvironment in Infants Born Very Preterm in NICU (PHASE1)
- Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia or Death in Extremely Preterm Neonates (PHASE3)
- Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP). (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- autologous cord blood mononuclear cells CI brief — competitive landscape report
- autologous cord blood mononuclear cells updates RSS · CI watch RSS
- Guangdong Women and Children Hospital portfolio CI
Frequently asked questions about autologous cord blood mononuclear cells
What is autologous cord blood mononuclear cells?
How does autologous cord blood mononuclear cells work?
What is autologous cord blood mononuclear cells used for?
Who makes autologous cord blood mononuclear cells?
What development phase is autologous cord blood mononuclear cells in?
What are the side effects of autologous cord blood mononuclear cells?
Related
- Manufacturer: Guangdong Women and Children Hospital — full pipeline
- Therapeutic area: All drugs in Regenerative Medicine
- Indication: Drugs for Treatment of cerebral palsy
- Compare: autologous cord blood mononuclear cells vs similar drugs
- Pricing: autologous cord blood mononuclear cells cost, discount & access